Shots:

• The COLUMBUS-AMD trial evaluates the clinical efficacy- safety & immunogenicity of CHS-201 (q4w for up to 48wks.) vs Lucentis in a ratio (1:1) in 477 patients with newly diagnosed subfoveal nAMD
• The results showed a mean BCVA improvement from baseline @8wks. with an equal median change in both treatment groups- patients experienced similar reductions in FCP & FCS retinal thickness along with total lesion area. The therapy also showed a similar reduction in the proportion of patients with active CNV leakage & an increase in the fluid-free macula
• The FDA has accepted the BLA for CHS-201’s review with an anticipated PDUFA date is Aug 2- 2022. If approved- the company plans to launch CHS-201 in the US in H2’22

  | Ref: Globe Newswire | Image: Coherus